Abstract:Abstract Introduction Schizophrenia is a mental health condition that severely impacts well-being. Cognitive impairment is among its core features, often presenting well before the onset of psychosis, underscoring a critical need to study it in the psychosis proneness stage, to maximize the benefits of interventions and to improve clinical outcomes. However, given the heterogeneity of cognitive impairment in this population, a one-size-fits-all approach to therapeutic interventions would likely be insufficient. Thus, identifying cognitive subtypes in this population is crucial for tailored and successful therapeutic interventions. Here we identify, validate, and characterize cognitive subtypes in large CHR samples and delineate their baseline and longitudinal cognitive and functional trajectories. Methods Using machine learning, we performed cluster analysis on cognitive measures in a large CHR sample (CHR (n = 764) HC (n = 280)) from the North American Prodrome Longitudinal Study (NAPLS) 2, and independently validated our findings with an equally large sample using NAPLS 3. By utilizing several statistical approaches, we compared the clusters on cognition and functioning at baseline, and longitudinally. We further delineate the conversion status within those clusters. Results Two main cognitive clusters were identified, impaired and intact across all cognitive domains compared to controls. The differences at baseline between the cognitively intact cluster and controls were found in the verbal abilities and attention and working memory domains. Longitudinally, those in the cognitively impaired cluster group demonstrated an overall floor effect and did not deteriorate further over time. However, a catch up trajectory was observed in the attention and working memory domain. This group had higher instances of conversion overall, with these converters having significantly more psychotic disorder diagnosis versus bipolar disorder, than those with intact cognition. In the cognitively intact group, we observed differences in the trajectory based on their conversion status, where those who start with intact cognition and later convert, demonstrate a sharp decline in attention and functioning. Functioning was significantly better in the cognitively intact than in the impaired group at baseline. Most of the cognitive trajectories demonstrate a meaningful positive relationship with functional ones. Conclusion Our findings provide evidence for intact and impaired cognitive subtypes in youth at CHR, independent of their conversion status. They further indicate that attention and working memory are important to distinguish between the CHR with intact cognition and controls. The cognitively intact CHR group becomes less attentive after conversion, while the cognitively impaired one demonstrates a catch up trajectory on both attention and working memory. Overall, early evaluation, covering several cognitive domains, is crucial for identifying trajectories of improvement and deterioration for the purpose of tailoring intervention for improving outcomes in individuals at CHR for psychosis.

Subtypes of Clinical High Risk for Psychosis That Predict Antipsychotic Effectiveness in Long-Term Remission

Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period

Neuroanatomical Heterogeneity and Homogeneity in Individuals at Clinical High Risk for Psychosis

Antipsychotic Prescription, Assumption and Conversion to Psychosis: Resolving Missing Clinical Links to Optimize Prevention Through Precision

Antipsychotic Exposure in Clinical High Risk of Psychosis

Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study

Two-Year Follow-Up of A Chinese Sample at Clinical High Risk for Psychosis: Timeline of Symptoms, Help-Seeking and Conversion

Individualized Risk Components Guiding Antipsychotic Delivery in Patients with a Clinical High Risk of Psychosis: Application of a Risk Calculator

Further Evidence That Antipsychotic Medication Does Not Prevent Long-Term Psychosis in Higher-Risk Individuals

Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity

Analysis of related factors of clinical outcome in patients with clinical high risk syndromes

The characteristics and clinical outcomes of a pluripotent high-risk group with the potential to develop a diverse range of psychiatric disorders

Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-Year Cohort of 517 Individuals at Clinical High Risk from the SHARP (shanghai at Risk for Psychosis).

Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis

When to Initiate Antipsychotic Treatment for Psychotic Symptoms: at the Premorbid Phase or First Episode of Psychosis?

Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (shanghai at Risk for Psychosis-Phase 2)

A Comparison of Conversion Rates, Clinical Profiles and Predictors of Outcomes in Two Independent Samples of Individuals at Clinical High Risk for Psychosis in China

Cognitive subtypes in youth at clinical high risk for psychosis

Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines

SU39. Do Baseline Clinical and Neurocognitive Features Predict Conversion in Individuals with Clinical High Risk to Psychosis in Shanghai?

Cognitive functions following initiation of antipsychotic medication in adolescents and adults at clinical high risk for psychosis: a naturalistic sub group analysis using the MATRICS consensus cognitive battery